THR-317 in diabetic macular edema - development in collaboration with ThromboGenics
ThromboGenics also allows for BioInvent to have a 40% equity stake in THR-317, an ophthalmologic formulation of TB-403, provided it chooses to contribute half of the development costs. As earlier communicated, BioInvent is currently evaluating how to ensure that the value of this project is optimized. The product is currently in a Phase II clinical study for the treatment of patients with diabetic macular edema. The study will evaluate the safety and efficacy of two dose levels of THR-317 and plans to include a total of 50 patients.
Patents for the antibody have been granted in Europe, the US, Japan and several additional countries, and patent applications are pending in further countries.